MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Business”), a clinical stage pharmaceutical firm dedicated to extending healthy and balanced life-span, today revealed that the very first individual has actually been signed up in the Company’s Phase 2 clinical test of lead candidate MYMD-1, a dental immune regulator drug, as a treatment for postponing aging as well as increasing healthy life-span.
The key endpoint for the Stage 2 double-blind, placebo-controlled scientific test is to accomplish a decrease in the flowing degrees of (TNF-α), growth necrosis variable receptor I (TNFRI) as well as IL-6. TNF-α as well as IL-6 are the healthy proteins in the body that create swelling as well as help turn on the procedure of aging. The second procedures of the trial will be the safety, tolerability, as well as pharmacokinetics in this populace of individuals.
” In a Phase 1 professional test of MYMD-1, we showed the drug’s statistically significant effectiveness in lowering levels of TNF-α, a principal in causing pathological aging, in the blood. The FDA has accepted TNF-α reduction as the key endpoint for our Stage 2 research, which our company believe positions us well for an effective Stage 2 end result,” said Chris Chapman, M.D., Head Of State, Supervisor and Principal Medical Policeman of MyMD. “The initiation of client registration in this research study advancements our objective to slow the aging process, stop loss of muscle tissue in aging, limitation frailty, and expand healthy life-span.”
MyMD has actually mentioned that there are no FDA-approved medications for dealing with aging conditions and expanding healthy and balanced life-span human beings, a market expected to be a minimum of $600 billion by 20251 according to a major investment bank. TNF-α blockers are the most recommended medicines by income, a worldwide market of about $40 billion per year,2 and also, according to Nature Aging journal,3 a stagnation in aging that would enhance life expectancy by one year is worth $38 trillion as well as by one decade deserves $367 trillion.
In addition to aging, MYMD-1’s distinctive action in regulating the body immune system and also treating persistent swelling is being developed for the treatment of autoimmune illness, including rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes, and also inflammatory bowel condition.
” We intend to begin composing protocols for a Phase 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The increasing occurrence of rheumatoid arthritis and also other autoimmune and inflammatory diseases are driving demand for TNF preventions like MYMD-1, as well as we believe our by mouth carried out medication with very reduced poisoning would be turbulent to the $60 billion market for RA if authorized by the FDA for this indicator.”
Rheumatoid arthritis impacts around 40 million people around the world.4.
Initially established for autoimmune diseases, MYMD-1’s primary purpose is to slow the aging process, protect against sarcopenia and frailty, as well as expand healthy and balanced lifespan. Because it can go across the blood-brain barrier as well as access to the main nervous system (CNS), MYMD-1 is additionally positioned to be a feasible therapy for brain-related problems. Its system of action as well as efficacy in illness consisting of several sclerosis (MS) and thyroiditis have been examined through cooperations with a number of scholastic establishments. MYMD-1 is also showing assurance in pre-clinical researches as a possible therapy for article- COVID-19 issues and as an anti-fibrotic as well as anti-proliferation restorative.
MYMD-1 has revealed efficiency in pre-clinical researches in controling the body immune system by executing as a selective prevention of growth death factor-alpha (TNF-α), a chauffeur of persistent swelling. Unlike other therapies, MYMD-1 has been shown in these pre-clinical researches to selectively obstruct TNF-α when it becomes overactivated in autoimmune diseases and also cytokine storms, but not block it from doing its typical work of being an initial responder to any regular sort of moderate infection. MYMD-1’s ease of dental dosing is one more differentiator compared to currently available TNF-α blockers, every one of which call for shipment by shot or mixture. No authorized TNF inhibitor has ever been dosed by mouth. In addition, the drug is not immunosuppressive and also has not been revealed to cause the major adverse effects usual with traditional therapies that deal with swelling.
About MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific phase pharmaceutical company committed to extending healthy life-span, is concentrated on creating 2 novel restorative systems that deal with the causes of condition rather than just dealing with the signs and symptoms. MYMD-1 is a medication system based on a clinical phase tiny particle that regulates the immune system to manage TNF-α, which drives chronic swelling, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to postpone aging, increase durability, as well as treat autoimmune diseases as well as COVID-19- linked depression. The Company’s second medication system, Supera-CBD, is being established to deal with chronic pain, addiction as well as epilepsy. Supera-CBD is a novel synthetic by-product of cannabidiol (CBD) as well as is being developed to address and improve upon the rapidly growing CBD market, that includes both FDA accepted drugs and also CBD products not presently regulated as medications. To find out more, go to www.mymd.com.